Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
Reshma A. Rangwala, Robert D. Leone, Yunyoung Claire Chang et al. · Autophagy · 2014
Blocking autophagy with hydroxychloroquine (HCQ) augments cell death associated with alkylating chemotherapy in preclinical models. This phase I study evaluated the maximum tolerated dose (MTD), safety, preliminary activity, pharmacokinetics, and pharmacodynamics of HCQ in combination with dose-intense temozolomide (TMZ) in patients with advanced solid malignancies. Forty patients (73% metastatic melanoma) were treated with oral HCQ 200 to 1200 mg daily with dose-intense oral TMZ 150 mg/m (2) daily for 7/14 d. This combination was well tolerated with no recurrent dose-limiting toxicities observed. An MTD was not reached for HCQ and the recommended phase II dose was HCQ 600 mg twice daily combined with dose-intense TMZ. Common toxicities included grade 2 fatigue (55%), anorexia (28%), nausea (48%), constipation (20%), and diarrhea (20%). Partial responses and stable disease were observed in 3/22 (14%) and 6/22 (27%) patients with metastatic melanoma. In the final dose cohort 2/6 patients with refractory BRAF wild-type melanoma had a near complete response, and prolonged stable disease, respectively. A significant accumulation in autophagic vacuoles (AV) in peripheral blood mononuclear cells was observed in response to combined therapy. Population pharmacokinetics (PK) modeling, individual PK simulations, and PK-pharmacodynamics (PD) analysis identified a threshold HCQ peak concentration that predicts therapy-associated AV accumulation. This study indicates that the combination of high-dose HCQ and dose-intense TMZ is safe and tolerable, and is associated with autophagy modulation in patients. Prolonged stable disease and responses suggest antitumor activity in melanoma patients, warranting further studies of this combination, or combinations of more potent autophagy inhibitors and chemotherapy in melanoma.
Cited by 367 works. doi:10.4161/auto.29118
Authors
- Reshma A. Rangwala
- Robert D. Leone
- Yunyoung Claire Chang
- Leslie Anne Fecher
- Lynn Mara Schuchter
- Amy Kramer
- Kay-See Tan
- Daniel F. Heitjan
- Glenda Rodgers
- Maryann Gallagher
- Shengfu Piao
- Andrea B. Troxel
- Tracey L. Evans
- Angela M. DeMichele
- Katherine L. Nathanson
- Peter James O'Dwyer
- Jonathon Kaiser
- Laura Pontiggia
- Lisa E. Davis
- Ravi K. Amaravadi
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
- What's going on 放射線 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. N Engl J Med. 2005; 352: 987-96. PMID: 15758009.--神経膠腫に対する治療として、放射線治療とテモゾロマイドの併用が世界的な標準的治療となりうることを示唆する論文
- Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
- Pancreatic cancers require autophagy for tumor growth
- Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
- Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
- Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
- Hydroxychloroquine concentration–response relationships in patients with rheumatoid arthritis
- Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis